51 studies found for:    ac-220
Show Display Options
Rank Status Study
1 Active, not recruiting Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
2 Completed A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
3 Active, not recruiting Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Compound AC220
4 Completed A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Conditions: Acute Myeloid Leukaemia;   High Risk Myelodysplastic Syndrome
Interventions: Drug: Plerixafor;   Drug: AC220;   Drug: Ganetespib
5 Completed A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Conditions: Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndrome;   AML;   MDS
Intervention: Drug: AC220
6 Recruiting AC220 With 5-Aza or Low Dose Cytarabine
Condition: Leukemia
Interventions: Drug: Quizartinib;   Drug: Cytarabine;   Drug: AZA
7 Active, not recruiting A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute,
Intervention: Drug: AC220
8 Active, not recruiting A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
9 Active, not recruiting Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
10 Recruiting An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Condition: AML
Interventions: Drug: Quizartinib;   Drug: Salvage Chemotherapy
11 Recruiting Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Condition: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions: Other: laboratory biomarker analysis;   Drug: quizartinib;   Drug: sorafenib tosylate
12 Completed
Has Results
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
13 Completed The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
14 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
15 Completed
Has Results
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Condition: Chronic Primary Insomnia
Interventions: Drug: almorexant;   Drug: Placebo;   Drug: zolpidem
16 Active, not recruiting Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906;   Drug: erlotinib;   Drug: placebo
17 Active, not recruiting Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Chronic Hepatitis B
Interventions: Drug: entecavir;   Drug: Other anti-HBV medication
18 Not yet recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
19 Completed This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
20 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years